Repros Therapeutics Inc. is a development-stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s Androxal is an oral therapy that normalizes testicular function, for the treatment of low testosterone due to secondary hypogonadism and Proellex is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. The Company’s primary product candidate, Androxal is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. The Company’s Proellex product candidate for female reproductive health is a chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis.